Global Mebendazole Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Chewable Tablets, Oral Suspension, and Tablets), By Applications (Adult and Children), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Mebendazole Market Insights Forecasts to 2033

• The Global Mebendazole Market Size was estimated at USD 246.27 Million in 2023
• The Market Size is expected to Grow at a CAGR of around 5.01% from 2023 to 2033
• The Worldwide Mebendazole Market Size is expected to reach USD 401.66 Million by 2033
• North America is predicted to Grow at the fastest CAGR throughout the projection period

The Global Mebendazole Market Size is predicted to exceed USD 401.66 Million by 2033, growing at a CAGR of 5.01% from 2023 to 2033.

Market Overview

The mebendazole market involves the development, production, and distribution of the mebendazole medications, widely used as an anti-parasitic drug for treating worm infestations like roundworm, hookworm, and whipworm, serving both human and veterinary healthcare needs. Mebendazole is a benzimidazole anthelmintic used to treat worm infections and helminth infections. It prevents worms from absorbing sugar, causing them to lose energy and die. Mebendazole inhibits microtubule production by binding to the colchicine binding site of β-tubulin, blocking the polymerization of tubulin dimers in parasite intestinal cells. This disrupts glucose uptake and the parasites digestive and reproductive capacities, leading to immobilization, egg production hindrance, and helminth death. Mebendazole is an FDA-approved drug used extensively in anthelmintic therapy with a good safety profile for human use. Its primary action is through its inhibitory effect on tubulin polymerization, resulting in the loss of cytoplasmic microtubules.

Several government initiatives are driving the market growth. For instance, the National Deworming Day is a public health initiative by the Ministry of Health and Family Welfare of India aimed at making every child worm-free. Soil-transmitted helminths, transmitted through contaminated soil, can cause anemia, malnutrition, impaired physical, mental, and cognitive development, and reduced school participation. The goal is to deworm all children aged 1-19 through schools and Anganwadi Centers, improving their overall health, nutritional status, access to education, and quality of life.

The rising prevalence of helminthiasis accelerated the need for anthelminthic drugs such as mebendazole, which resulted in market expansion. For example, the data provided by National Library of Medicine states that parasitic helminth infections, affecting over 1 billion people globally, are a major global health issue, particularly in tropical and sub-tropical countries in Africa, South America, and the Asia-Pacific, due to severe poverty and sub-standard housing and sanitation, and are closely linked to severe poverty.

Report Coverage

This research report categorizes the global mebendazole market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global mebendazole market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global mebendazole market.

Driving Factors:

The mebendazole market is expanding in developing regions owing to an increase in parasitic infections. Mebendazole is a preferred option among healthcare providers because of its high effectiveness and ease of administration. The veterinary health sector is experiencing significant growth due to its widespread use in treating parasitic infections in animals. The market is expected to grow further, supported by advancements in pharmaceutical formulations and the development of combination therapies. Chewable tablets and oral suspensions facilitate easier administration for children and elderly patients, thereby enhancing adherence to treatment regimens. Therapies that combine mebendazole with other treatments are showing greater efficacy in eradicating a wider variety of parasitic infections. There are opportunities for growth in the mebendazole market in developing regions, driven by government initiatives, public health programs, and cost-effective formulations.

Restraining Factors

The repeated use of the mebendazole medications leads to drug resistance, side effects associated with mebendazole, high cost of the mebendazole medications, stringent regulatory framework, and lack of awareness of the mebendazole drugs may limit the growth of the market.

Market Segmentation

The global mebendazole market share is classified into dosage form, applications, and distribution channel.

• The tablets segment dominated the market with 74.82% in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global mebendazole market is divided into chewable tablets, oral suspension, and tablets. Among these, the tablets segment dominated the market with 74.82% in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to the ease of administration, longer shelf life, patient convenience, greater physical and chemical stability, precise dosing, cost effectiveness, and availability of the novel drug delivery system, such as controlled drug delivery system, sustained drug delivery system, rapid dissolution and disintegration rate.

• The children segment accounted for the largest market share of 57.25% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the applications, the global mebendazole market is categorized into adult and children. Among these, the children segment accounted for the largest market share of 57.25% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The mebendazole market focuses on children primarily, as it serves to treat parasitic infections such as pinworm, roundworm, and hookworm. Its cost-effectiveness, safety, and inclusion in public health programs drive the market. Growth is aided by innovative formulations and awareness campaigns, while success is driven by child-friendly packaging and rising demand in areas where parasitic infections are prevalent.

• The hospital pharmacies segment held the largest market share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global mebendazole market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment held the largest market share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is attributed to the collaboration of hospital pharmacies and hospitals, availability of skilled pharmacists, accessibility of a wide stock of the mebendazole tablets, provision of the counselling and dispensing of drugs, and offering cost-effective medications.

Regional Segment Analysis of the Global Mebendazole Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the global mebendazole market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the global mebendazole market over the predicted timeframe. The global mebendazole market is expanding as a result of intensified research and development strategies and the growing incidence of pinworm infections. It is anticipated that the demand for these drugs will increase owing to the high incidence of helminth infections and increasing healthcare expenditure. Market growth is being driven by countries such as India and China, owing to their substantial populations and enhanced healthcare infrastructure. Market growth is additionally fueled by the increasing awareness of parasitic infections and public health initiatives. Pharmaceutical companies are working on the development of sophisticated formulations to enhance treatment outcomes.

North America is anticipated to grow at the fastest CAGR throughout the projected timeframe. The market for mebendazole is driven by high awareness, advanced healthcare systems, and major pharmaceutical companies. The United States is growing in North America ascribed to R&D expenditure and is a major player in wholesale drugs and finished dosage construction. The market operates as a free economy, promoting transparent trade practices and limiting anti-competitive practices. Mebendazole is in high demand due to gastrointestinal parasitic diseases in vulnerable populations, and the growing emphasis on preventive healthcare measures boosts its adoption. Mebendazole is additionally preferred in pediatric healthcare due to its effectiveness and minimal side effects.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global mebendazole market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company Limited
• Bayer AG
• Mylan N.V.
• GlaxoSmithKline plc
• Johnson and Johnson
• Amgen Inc.
• Bristol- Myers Squibb Company
• Gilead Sciences, Inc.
• Roche Holding AG
• AbbVie Inc.
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2024, Johnson & Johnson committed to extending its global product donations of VERMOX Chewable (Mebendazole chewable 500mg tablets), its intestinal worm treatment, through 2030. The five-year extended commitment will ensure up to one billion doses of the medicine are available to treat children and women of reproductive age in endemic countries, or up to 200 million doses per year.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global mebendazole market based on the below-mentioned segments:

Global Mebendazole Market, By Dosage Form

• Chewable Tablets
• Oral Suspension
• Tablets

Global Mebendazole Market, By Applications

• Adult
• Children

Global Mebendazole Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Global Mebendazole Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa